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Gene expressionAffymetrix Human Gene 1.0-ST arrays were used to assess the gene expression proﬁles of kidney transplant
patients who presented with donor-speciﬁc antibodies (DSAs) but showed normal biopsy histopathology and
did not develop antibody-mediated rejection (AMR). Biopsy and whole-blood proﬁles for these DSA-positive,
AMR-negative (DSA+/AMR−) patients were compared to both DSA-positive, AMR-positive (DSA+/AMR+)
patients as well as DSA-negative (DSA−) controls. While individual gene expression changes across sample
groupswere relatively subtle, gene-set enrichment analysis using previously identiﬁed pathogenesis-based tran-
scripts (PBTs) identiﬁed a clear molecular signature involving increased rejection-associated transcripts in
AMR− patients. Results from this study have been published in Kidney International (Hayde et al., 2014 [1])
and the associated data have been deposited in the GEO archive and are accessible via the following link:
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE50084
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Antibody-mediated rejection (AMR) is the major cause of late
kidney transplant failure [2,3]. While some patients presenting with
donor-speciﬁc anti-human leukocyte antigen (HLA) antibodies (DSAs)
develop either chronic or acute AMR and ultimately reject their
allograft, others maintain stable functioning allografts and continue to
demonstrate normal biopsy histopathologies. In this study [1], we
sought to determine if any differences in gene expression between
DSA+/AMR+ patients, DSA+/AMR− patients, and DSA− controls
might explain this phenomenon.
Study population
The study population consisted of 263 patients who underwent
anti-HLA antibody testing at the time of biopsy for worsening kidney
function and/or proteinuria. Antibody presence was detected using
Luminex HLA Single Antigen Bead assays (LABScreen, One Lambda,
Canoga Park, CA) with a mean ﬂuorescence intensity (MFI) N=
1000 used as a cutoff for identiﬁcation of DSA+ patients. Demo-
graphic and clinical characteristics, as well as Banff histopathology
scores [4] for these patients are shown in Table 1. From this largerr the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Table 1
Study population. Data are reported as proportions, median (interquartile range), or mean (s.d.) as appropriate; statistical differences were determined using ANOVA for continuous var-
iables and Fisher's exact test for categorical variables; in all cases a p-value of b 0.05was considered signiﬁcant. AMR, antibody-mediated rejection; CsA, cyclosporine; DSA, donor-speciﬁc
antibody; MFI, mean ﬂuorescence intensity; MMF, mycophenolate mofetil; PRA, panel reactive antibody; Pred, prednisone; Tac, tacrolimus.
DSA+/AMR+ (n = 46) DSA+/AMR− (n = 25) DSA− (n = 50) p-Value
Demographics
Median age (years) 44 (34–48) 49 (35–62) 49 (37–57) 0.12
Sex, male 57% 60% 66% 0.63
Race, African-American 30% 36% 40% 0.62
Deceased-donor transplant 63% 72% 80% 0.18
Previous transplant 11% 16% 12% 0.82
History of previous acute rejection 24% 16% 6% 0.047
Median time to biopsy (years) 4.1 (0.2–23.8) 0.3 (0.2–8.2) 0.5 (0.1–10.7) b0.001
Clinical characteristics
Immunosuppression 0.45
Tac/MMF/Pred 65% 80% 72%
CsA/MMF/Pred 7% 0.00% 2%
Tac/Pred 15% 4% 6%
Other 13% 16% 20%
Class I DSA frequency 70% 72% NA 0.83
Class II DSA frequency 70% 44% NA 0.04
Class I DSA MFI, median 3467 (0–5326) 2041 (0–5642) NA 0.7
Class II DSA MFI, median 4958 (0–9909) 0 (0–7317) NA 0.04
Class I PRA, median, % 51 (19–74) 52 (17–84) 0 (0–2) 0.61
Class II PRA, median, % 63 (50–79) 9 (0–53) 0 0.004
Banff histopathology scores
Glomerulitis 0.72 ± 0.75 0.24 ± 0.60 0.08 ± 0.27 b0.001
Peritubular capillaritis 1.28 ± 1.1 0.42 ± 0.77 0.22 ± 0.62 b0.001
Interstitial inﬂammation 1.3 ± 0.92 0.64 ± 0.81 0.38 ± 0.60 b0.001
Tubulitis 0.48 ± 0.75 0.08 ± 0.28 0.1 ± 0.30 0.05
Intimal arteritis 0.11 ± 0.32 0 0.02 ± 0.14 0.67
Chronic glomerulopathy 0.89 ± 1.04 0.08 ± 0.4 0 b0.001
Mesangial matrix 0.78 ± 0.79 0.52 ± 0.77 0.02 ± 0.40 0.002
Interstitial ﬁbrosis 1.33 ± 0.81 0.88 ± 0.90 1.06 ± 0.89 0.13
Tubular atrophy 1.49 ± 0.89 0.8 ± 0.87 0.92 ± 0.83 0.003
Chronic vascular score 0.69 ± 0.75 0.55 ± 0.60 0.69 ± 0.79 0.86
Arteriolar hyalinization 1.04 ± 1.21 0.48 ± 0.82 0.52 ± 0.84 0.09
(Signiﬁcant p-values (b = 0.05) are higlighted in bold.)
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Board-approved ‘Immune Monitoring Study’ and had biopsy or
whole-blood samples taken for expression proﬁling as indicated in
Table 2.
Quality control, exploratory analysis, and linear modeling
For both biopsy and blood samples separately, raw probe intensities
from Affymetrix Human Gene 1.0-ST array CEL ﬁles were background
corrected, quantile normalized, and median-polish summarized using
the robust multiarray average (RMA) method from the R/Bioconductor
(http://www.bioconductor.org) oligo package [5]. Normalization of
probe intensities was visualized using density plots (Fig. 1). Annotation
informationwas obtained from theHumanGene 1.0 transcript cluster da-
tabase, hugene10sttranscriptcluster.db, and control probes were removed.
Exploratory data analysis using both heatmaps based onbetween-sample
Pearson correlation coefﬁcient as well as multidimensional scaling plots
(shown in Fig. 1) indicated that samples from the three clinical pheno-
types were largely overlapping. Differences in gene expression were
determined using the limma package [6] to ﬁt gene-wise linear models
to log2 scaled data with a Benjamini–Hochberg-corrected p-value cutoff
of 0.01 and a log-odds probability of differential expression (B-statistic)
greater than zero. As shown in Fig. 2, the vast majority of individualTable 2
Expression proﬁling study design.
Biopsy Blood
DSA+/AMR+ n = 28 n = 28
DSA+/AMR− n = 13 n = 14
DSA− n = 20 n = 12gene expression changes identiﬁed in each of the sample group compar-
isons were relatively small (b1.5 fold change).
Gene ontology and gene-set enrichment analysis
Gene ontology (GO) analysis was performed using theGOstats pack-
age [7], which carries out a hypergeometric test for enrichment of tran-
scripts in speciﬁcally deﬁned categories corresponding to distinct
molecular functions or biological processes. In DSA+/AMR− biopsy
samples, enrichment of genes related to cytokine production, including
those involved in activation and regulation of type I interferon (alpha-
and beta-interferon) was observed relative to DSA− samples, while
DSA+/AMR+ samples showed enrichment relative to DSA− samples
of genes implicated in all aspects of the immune response, including
those pertaining to the regulation and activation of T-cells and B-cells,
natural killer cells, leukocytes, and cytokine production. Genes involved
in the activation, regulation, and differentiation of T cells, natural killer
cells, leukocytes, and interleukins were also enriched in DSA+/AMR+
whole-blood samples when compared to DSA+/AMR− samples.
DSA+/AMR− blood samples however, did not show any enrichment
of genes related to immune response when compared with DSA−
controls.
We also carried out a gene-set analysis using both human-speciﬁc
gene-sets derived from the Broad's MSigDB [8] by researchers at the
Walter and Eliza Hall Institute's Bioinformatics Division (available
for download at http://bioinf.wehi.edu.au/software/MSigDB/), as well
as custom gene-sets created from groups of previously described
pathogenesis-based transcripts (PBTs) which have been shown to be
useful in molecular classiﬁcation of antibody-mediated rejection [9].
The custom PBT gene-sets (detailed in Table 3)were generated bymap-
ping the genes listed at the University of Alberta's Transplant Applied
Fig. 1. Normalization and exploratory data analysis. Panels (a) and (b) show the pre- and post-normalization density plots of probe intensities for biopsy and blood samples respectively.
Panels (c) and (d) show the multidimensional scaling plots for biopsy and blood samples respectively and were generated using the limma plotMDS function which calculates sample
distances based on the root-mean-square log2 fold-change deviation for the top 500 genes distinguishing different sample classes. Sample classes are colored as follows: DSA+/
AMR+ (blue), DSA+/AMR− (green), DSA− (red).
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gene_lists.html) to HUGO gene identiﬁers and then converting to stan-
dard GMT format. The enrichment analysis was carried out using the
limma romer function which implements a parametric re-sampling ap-
proach to gene-set enrichment analysis suitable for use with linear
models. In biopsy samples, GRIT, CAT1, NKAT, CMAT, DSAST, andFig. 2.Differentially expressed genes. Volcano plots indicate that individual changes in gene expre
shown on the X-axis and the log-odds of differential expression is shown on the Y-axis. Genes wENDAT transcripts were found to be signiﬁcantly up-regulated in both
DSA+/AMR+ and DSA+/AMR− samples relative to DSA− controls,
while GRIT and DSAST transcripts were also expressed at signiﬁcantly
higher levels in DSA+/AMR+ biopsies compared to DSA+/AMR− bi-
opsies (Fig. 3). BAT and AMA transcripts were up-regulated in the
DSA+/AMR− group relative to DSA− controls but not in the DSA+/ssion between different clinical classes are relatively subtle. Log2 fold-change in expression is
ith a log-odds probability of differential expression greater than zero are highlighted in red.
Table 3
Pathogenesis-based transcript gene sets.
KT2: kidney-speciﬁc transcripts (n = 63)
GRIT: gamma-interferon and rejection-induced transcripts (n = 50)
CAT1: cytotoxic T-cell-associated transcripts (n = 143)
BAT: B-cell-associated transcripts (n = 50)
NKAT: natural killer cell-associated transcripts (n = 134)
CMAT: constitutive macrophage-associated transcripts (n = 71)
AMA: alternate macrophage-associated transcripts (n = 94)
DSAST: transcripts differentially expressed between rejection-classiﬁed DSA+ and
DSA− patient biopsies (n = 21)
ENDAT: endothelial cell-associated transcripts (n = 114)
TREG: regulatory T-cell-associated transcripts (n = 33)
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blood samples, CMAT transcripts were the only clearly up-regulated
gene-set in the DSA+/AMR− to DSA− comparison (p-value = 0.03).
In DSA+/AMR+ samples, CAT, CMAT, and AMA transcript were up-
regulated compared toDSA− controls,while AMAandDSAST transcripts
were also up-regulated compared to the DSA+/AMR− group.
Discussion
These results indicate thatwhile someDSA+/AMR− biopsies retain
normal histopathologies, they do however show increased levels of
rejection-associated transcripts, including those related to interferon,
T-cell, B-cell, natural killer cell, and macrophage function. Despite this
increased level of rejection-associated transcripts, during a three-year
follow-up, only four patients (17%) developed AMR while nine (43%)
lost their DSA, highlighting the need for further study to develop a
more complete understanding of the mechanisms of allograft protec-
tion. The analysis of whole-blood gene expression showed an increased
immune response in DSA+/AMR+, but not in DSA+/AMR− patients,
suggesting an ongoing immune response in the allograft rather than a
systematic immune response.Fig. 3. Pathogenesis-based transcript gene-set expression. Shown here are the median log2 ex
p-values are taken from the limma romer analysis and are indicative of signiﬁcant up-regulatioDisclosure
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